MX2021013248A - Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. - Google Patents
Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen.Info
- Publication number
- MX2021013248A MX2021013248A MX2021013248A MX2021013248A MX2021013248A MX 2021013248 A MX2021013248 A MX 2021013248A MX 2021013248 A MX2021013248 A MX 2021013248A MX 2021013248 A MX2021013248 A MX 2021013248A MX 2021013248 A MX2021013248 A MX 2021013248A
- Authority
- MX
- Mexico
- Prior art keywords
- disclosure describes
- compositions including
- dosage regimens
- including anti
- rsv antibodies
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229940121468 nirsevimab Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
En un aspecto, la presente divulgación describe métodos para tratar o prevenir la infección por VRS en un paciente que lo necesita. Los métodos incluyen regímenes de dosificación para administrar una composición que incluye una dosis fija de un anticuerpo monoclonal anti-VRS o un fragmento de unión a antígeno del mismo. En otro aspecto, la presente divulgación describe composiciones farmacéuticas para el tratamiento o la prevención de la infección por VRS. En otro aspecto más, la presente divulgación describe una dosis unitaria farmacéutica que incluye nirsevimab.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840701P | 2019-04-30 | 2019-04-30 | |
| PCT/US2020/030619 WO2020223435A1 (en) | 2019-04-30 | 2020-04-30 | Dosage regimens for and compositions including anti-rsv antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013248A true MX2021013248A (es) | 2022-01-24 |
Family
ID=70779897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013248A MX2021013248A (es) | 2019-04-30 | 2020-04-30 | Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12024553B2 (es) |
| EP (1) | EP3962940A1 (es) |
| JP (1) | JP2022531205A (es) |
| KR (1) | KR20220002427A (es) |
| CN (1) | CN113825767A (es) |
| AU (1) | AU2020265676A1 (es) |
| BR (1) | BR112021020846A2 (es) |
| CA (1) | CA3138180A1 (es) |
| CO (1) | CO2021014370A2 (es) |
| EA (1) | EA202192776A1 (es) |
| IL (1) | IL287443A (es) |
| MX (1) | MX2021013248A (es) |
| SG (1) | SG11202111748TA (es) |
| TW (1) | TW202106333A (es) |
| WO (1) | WO2020223435A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023039584A2 (en) * | 2021-09-13 | 2023-03-16 | Medimmune Limited | Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| AU2014212268B2 (en) | 2013-02-01 | 2018-07-19 | Medimmune, Llc | Respiratory Syncytial Virus F protein epitopes |
| FR3008921B1 (fr) | 2013-07-23 | 2015-12-25 | Safran | Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece |
| EP3741390A1 (en) | 2014-01-15 | 2020-11-25 | Medlmmune, LLC | Rsv-specific antibodies and functional parts thereof |
| TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| CN110366429B (zh) | 2017-03-01 | 2024-10-11 | 免疫医疗有限公司 | 单克隆抗体的配制品 |
-
2020
- 2020-04-27 US US16/859,750 patent/US12024553B2/en active Active
- 2020-04-30 CN CN202080032470.XA patent/CN113825767A/zh active Pending
- 2020-04-30 EP EP20727466.3A patent/EP3962940A1/en active Pending
- 2020-04-30 KR KR1020217038129A patent/KR20220002427A/ko unknown
- 2020-04-30 US US17/606,614 patent/US20220204593A1/en active Pending
- 2020-04-30 TW TW109114519A patent/TW202106333A/zh unknown
- 2020-04-30 CA CA3138180A patent/CA3138180A1/en active Pending
- 2020-04-30 BR BR112021020846A patent/BR112021020846A2/pt unknown
- 2020-04-30 JP JP2021564373A patent/JP2022531205A/ja active Pending
- 2020-04-30 SG SG11202111748TA patent/SG11202111748TA/en unknown
- 2020-04-30 EA EA202192776A patent/EA202192776A1/ru unknown
- 2020-04-30 MX MX2021013248A patent/MX2021013248A/es unknown
- 2020-04-30 AU AU2020265676A patent/AU2020265676A1/en active Pending
- 2020-04-30 WO PCT/US2020/030619 patent/WO2020223435A1/en unknown
-
2021
- 2021-10-20 IL IL287443A patent/IL287443A/en unknown
- 2021-10-26 CO CONC2021/0014370A patent/CO2021014370A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138180A1 (en) | 2020-11-05 |
| CO2021014370A2 (es) | 2021-10-29 |
| US20220204593A1 (en) | 2022-06-30 |
| EP3962940A1 (en) | 2022-03-09 |
| CN113825767A (zh) | 2021-12-21 |
| US12024553B2 (en) | 2024-07-02 |
| TW202106333A (zh) | 2021-02-16 |
| BR112021020846A2 (pt) | 2022-01-18 |
| AU2020265676A1 (en) | 2021-11-18 |
| IL287443A (en) | 2021-12-01 |
| KR20220002427A (ko) | 2022-01-06 |
| JP2022531205A (ja) | 2022-07-06 |
| US20200347120A1 (en) | 2020-11-05 |
| EA202192776A1 (ru) | 2022-01-19 |
| SG11202111748TA (en) | 2021-11-29 |
| WO2020223435A1 (en) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
| MX348579B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| UA94899C2 (ru) | Фиксированное дозирование антител к her | |
| MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| MX2023002805A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos. | |
| MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
| MX2022008471A (es) | Anticuerpo anti-angptl3 y uso del mismo. | |
| BR112023026111A2 (pt) | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo | |
| MX2021008760A (es) | Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| MX2021013248A (es) | Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. | |
| EA201100884A1 (ru) | Моноклональные антитела анти-rhd | |
| CR20210685A (es) | Terapia de combinación | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| MX2022001065A (es) | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. | |
| MX2021004603A (es) | Dosificacion. | |
| MX2021008919A (es) | Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua). |